A Phase 2/3 interventional study of DA-001 and Placebo in Telogen Effluvium, Female Pattern Hair Loss and Female Pattern Hair Loss, Androgenic Alopecia, sponsored by Applied Biology, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Applied Biology, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..
Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2026, is the only one in phase 2/3, and was the 9th registered.
512 studies on the registry are indexed under Alopecia; 128 are open to participants now.
Browse Alopecia studies →3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:
Applied Biology, Inc. · Sites in Brazil, Italy
Ages 18–65 · Women only
Applied Biology, Inc. · Sites in Italy
Ages 18–65 · Women only
By country, each count listing its studies:
Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,120 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 60 across the 9 interventional studies, 150 across the 4 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
2 of the studies in Alopecia by Applied Biology, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06648850Phase 3Applied Biology, Inc.Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth | 2027-03-19 |
| NCT07397325Applied Biology, Inc.Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | 2027-02-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Alopecia by Applied Biology, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist. DA-001 was studied in a population of women that suffer from excessive hair shedding. DA-001 demonstrated significant reduction in hair shedding.
This study aims to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phenylephrine 2.5% Topical + TAAR agonist
Drug: DA-001
Placebo
Other: Placebo
Phenylephrine 2.5% Topical (per application volume - males 5mL and females 20mL)
Drug: Phenylephrine
DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)
Other: DA-001 Topical + DA-005 Oral (HIF-1α supplement)
Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Other: DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Phenylephrine Topical 0.25% + Intact Pro Topical
Drug: Phenylephrine Topical 0.25% + Intact Pro Topical
Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)
Other: Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)
Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution
Placebo Topical Solution
Phenylephrine 2.5% Topical
DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)
Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
Phenylephrine 0.25% + Intact Pro (50% stronger)
Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement)
Mean Change in Hair Shedding
Number of hairs shedding during brushing at target area
Time frame: Minutes [0,5]
Mean Change in Hair Shedding
Number of hairs shedding during brushing at target area
Time frame: Week [0, 4, 12, 24]
Mean Change in Target Area Hair Count (TAHC)
Number of hairs in a 1-cm² target scalp area
Time frame: Week [0, 4, 12, 24]
No study locations are listed for this record.
Plan to share: No
Start is estimated for May 2026; primary completion for Mar 2027, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenylephrine